Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Employment agrmnt
Quarterly results
Appointed director
Fortress Biotech, Inc. (FBIO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Amendments to Second Amended and Restated Bylaws",
"THIRD AMENDED AND RESTATED BYLAWS OF FORTRESS BIOTECH, INC. — A Delaware Corporation — THIRD AMENDED AND RESTATED BY-LAWS OF FORTRESS BIOTECH, INC. Adopted August 10, 2023 ARTICLE I OFFICES SECTION 1. Principal Office . The registered office of the corporation shall be located in such place as may be provided from time to time in the Certificate of Incorporation. SECTION 2. Other Offices . The corporation may also have offices at such other places both within and without the State of Delaware as the board of directors may from time to time determine or as the business of the corporation may require. ARTICLE II STOCKHOLDERS SECTION 1. Annual Meetings . The annual meeting of the stockholders of the corporation shall be held wholly or partially by means of remote communication or at such plac...",
"Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights"
05/15/2023 8-K Quarterly results
11/14/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
11/15/2021 8-K Quarterly results
Docs: "Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corporate Highlights"
08/16/2021 8-K Quarterly results
05/17/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "FORTRESS BIOTECH, INC. AND SUBSIDIARIES Consolidated Balance Sheets September 30, December 31, 2020 2019 ASSETS Current assets Cash and cash equivalents $ 218,389 $ 136,858 Accounts receivable 15,653 13,539 Inventory 1,052 857 Other receivables - related party 939 865 Prepaid expenses and other current assets 1,704 4,133 Total current assets 237,737 156,252 Property and equipment, net 12,114 12,433 Operating lease right-of-use asset, net 20,265 21,480 Restricted cash 1,645 16,574 Long-term investment, at fair value 11,723 11,148 Intangible asset, net 11,039 7,377 Other assets 1,356 1,158 Total assets $ 295,879 $ 226,422 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Accounts payable and accrued expenses $ 32,542 $ 35,451 Accounts payable and accrued expenses - related party 19 — ..."
08/10/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
Docs: "Fortress Biotech Reports Record First Quarter 2020 Financial Results and Recent Corporate Highlights"
11/12/2019 8-K Quarterly results
08/09/2019 8-K Quarterly results
05/10/2019 8-K Quarterly results
Docs: "FORTRESS BIOTECH, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets March 31, 2019 December 31, 2018 ASSETS Current assets Cash and cash equivalents $ 116,444 $ 65,508 Accounts receivable 8,022 5,498 Short-term investments 5,044 17,604 Inventory 629 678 Other receivables - related party 2,129 2,095 Prepaid expenses and other current assets 4,281 6,735 Current assets held for sale – 13,089 Total current assets 136,549 111,207 Property and equipment, net 11,833 12,019 Operating lease right-of-use asset, net 22,618 – Restricted cash 16,074 16,074 Long-term investment, at fair value 11,056 – Intangible asset 1,183 1,417 Other assets 1,225 276 Total assets $ 200,538 $ 140,993 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable and accrued expenses $ 37,073 $ 34,0..."
11/09/2018 8-K Quarterly results
Docs: "FORTRESS BIOTECH, INC. AND SUBSIDIARIES"
08/09/2018 8-K Quarterly results
Docs: "FORTRESS BIOTECH, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets June 30, December 31, 2018 2017 ASSETS Current assets Cash and cash equivalents $ 98,591 $ 113,915 Accounts receivable 5,321 7,758 Short-term investments 35,000 36,002 Cash deposits with clearing organizations 836 1,041 Receivables from broker-dealers and clearing organizations 11,412 7,395 Forgivable loans receivable 1,598 1,616 Securities owned, at fair value 3,812 1,985 Inventory 299 171 Other receivables - related party 775 618 Prepaid expenses and other current assets 13,880 12,680 Total current assets 171,524 183,181 Property and equipment, net 14,163 9,513 Restricted cash 17,389 17,387 Long-term investments, at fair value 565 1,390 Intangible assets 13,614 15,223 Goodwill 18,645 18,645 Other assets 966 611..."
05/10/2018 8-K Quarterly results
Docs: "FORTRESS BIOTECH, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets March 31, December 31, 2018 2017 ASSETS Current assets Cash and cash equivalents $ 124,020 $ 113,915 Accounts receivable 8,314 7,758 Short-term investments 37,002 36,002 Cash deposits with clearing organizations 1,041 1,041 Receivables from broker-dealers and clearing organizations 8,464 7,395 Forgivable loans receivable 1,534 1,616 Securities owned, at fair value 4,278 1,985 Inventory 222 171 Other receivables - related party 944 618 Prepaid expenses and other current assets 14,338 12,680 Total current assets 200,157 183,181 Property and equipment, net 12,278 9,513 Restricted cash 17,387 17,387 Long-term investments, at fair value 1,272 1,390 Intangible assets 14,400 15,223 Goodwill 18,645 18,645 Other assets 93..."
11/09/2017 8-K Quarterly results
Docs: "Fortress Biotech Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights – November 9, 2017 – Fortress Biotech, Inc. , a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2017. Dr. Lindsay A. Rosenwald, Fortress’ Chairman, President and Chief Executive Officer, said, “Fortress enjoyed strong third quarter performance, beginning with the formation of a new gene therapy subsidiary company, Aevitas Therapeutics. Fortress’ other subsidiaries also continued to achieve important corporate and clinical milestones during the quarter. Avenue dosed the first patient in its pivotal Phase 3 study..."
08/09/2017 8-K Quarterly results
05/10/2017 8-K Form 8-K - Current report
03/16/2017 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
11/01/2013 8-K Quarterly results
Docs: "Consolidated Balance Sheets September 30, 2013 December 31, 2012 ASSETS Cash and cash equivalents $ 106,267 $ 40,199 Prepaid and other current assets 279 393 Total current assets 106,546 40,592 Property & equipment net 452 51 Other 109 349 Total Assets $ 107,107 $ 40,992 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities $ 9,644 $ 5,132 Note payable, non-current 8,408 12,386 Other long-term liabilities 1,541 1,441 Total Liabilities 19,593 18,959 Stockholders' Equity 87,514 22,033 Total Liabilities and Stockholders' Equity $ 107,107 $ 40,992 CORONADO BIOSCIENCES, INC. AND SUBSIDIARY Consolidated Statements of Operations"
08/05/2013 8-K Amended existing or entered into new employment agreement with an officer, Quarterly results
Docs: "Amendment to Employment Agreement by and between Coronado Biosciences, Inc. and Dr. Karin Hehenberger, M.D., Ph.D",
"CORONADO BIOSCIENCES REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2013 Burlington, MA - August 5, 2013 - Coronado Biosciences, Inc. , a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today its financial results for the second quarter ended June 30, 2013."
05/08/2013 8-K Quarterly results
Docs: "CORONADO BIOSCIENCES REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2013 Burlington, MA - May 8, 2013 - Coronado Biosciences, Inc. , a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today its financial results for the first quarter ended March 31, 2013. “During the first quarter of 2013, Coronado remained focused on driving our clinical programs forward,” said Dr. Harlan F. Weisman, Coronado's Chairman and CEO. “We expect to report data from two large Phase 2 trials evaluating TSO in Crohn's disease during the second half of 2013: Top-line results from Coronado's TRUST-I trial in the U.S. and a second interim analysis from our development partner Dr. Falk Pharma's TR..."
08/08/2012 8-K Quarterly results
Docs: "Coronado Biosciences Reports Financial Results for the Second Quarter Ended June 30, 2012"
05/15/2012 8-K Quarterly results
Docs: "Coronado Biosciences Reports Financial Results for the First Quarter Ended March 31, 2012"
03/29/2012 8-K Quarterly results
Docs: "Coronado Biosciences Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2011"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy